{"DataElement":{"publicId":"5810390","version":"1","preferredName":"Monoclonal Antibody Administered Type","preferredDefinition":"A description of the monoclonal antibody that was administered.","longName":"4980706v1.0:2741175v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"4980706","version":"1","preferredName":"Monoclonal Antibody Administered","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment._The act of having given something (e.g., a medication or test).","longName":"4231491v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4231491","version":"1","preferredName":"Monoclonal Antibody","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","longName":"C20401","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D7D8BA-6B7E-127F-E040-BB89AD430ADE","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-17","modifiedBy":"ONEDATA","dateModified":"2014-03-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E119407-B3C7-5FA3-E050-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-24","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2741175","version":"1.1","preferredName":"Monoclonal Antibody Type","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment._Type; a subdivision of a particular kind of thing.","longName":"MAB_TYPE","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Campath","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-10C9-5F55-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":"2013-10-17","createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"KUMMEROA","dateModified":"2013-10-17","deletedIndicator":"No"},{"value":"Other MAb","valueDescription":"Other Monoclonal Antibody","ValueMeaning":{"publicId":"2741176","version":"1","preferredName":"Other Monoclonal Antibody","longName":"2741176","preferredDefinition":"Not otherwise specified.: An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FE9C-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-10D3-5F55-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ONEDATA","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Gemtuzumab (mylotarg, anti-CD33)","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-10DD-5F55-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ONEDATA","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Rituximab (Rituxan, anti-CD20)","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-10E7-5F55-E044-0003BA3F9857","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ONEDATA","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Monoclonal antibody (MAb)","valueDescription":"monoclonal antibody","ValueMeaning":{"publicId":"2568320","version":"1","preferredName":"monoclonal antibody","longName":"2568320","preferredDefinition":"monoclonal antibody","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-10F1-5F55-E044-0003BA3F9857","beginDate":"2008-05-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ONEDATA","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Infliximab (Remicade)","valueDescription":"Infliximab","ValueMeaning":{"publicId":"2567430","version":"1","preferredName":"Infliximab","longName":"2567430","preferredDefinition":"A monoclonal antibody that inhibits the function of TNF-alpha.  It is used in the treatment of rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D473-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-110A-5F55-E044-0003BA3F9857","beginDate":"2008-08-25","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ALEYR","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Etanercept (Enbrel)","valueDescription":"Etanercept","ValueMeaning":{"publicId":"2567429","version":"1","preferredName":"Etanercept","longName":"2567429","preferredDefinition":"A dimeric fusion protein comprised of a recombinant form of the extracellular ligand-binding portion of the human 75-kilodalton tumor necrosis factor receptor linked to the Fc portion of human immunoglobulin G1 (IgG1).  Clinical Use: Juvenile Arthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.  Clinical Trial: Bone Marrow Transplant and Adjuvant use for Caner-related Anorexia, Cachexia, and Stomatitis.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D472-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-111F-5F55-E044-0003BA3F9857","beginDate":"2008-08-25","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ALEYR","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Anti CD25 (Zenepax, Daclizumab, AntiTAC)","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"2576091","version":"1","preferredName":"Daclizumab","longName":"2576091","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"554A7B34-1134-5F55-E044-0003BA3F9857","beginDate":"2008-08-25","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"ALEYR","dateModified":"2008-08-25","deletedIndicator":"No"},{"value":"Radio labeled mAb","valueDescription":"Radiolabeled Monoclonal Antibody","ValueMeaning":{"publicId":"2751256","version":"1","preferredName":"Radiolabeled Monoclonal Antibody","longName":"2751256","preferredDefinition":"Any compound that has been joined with a radioactive substance.: An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiolabeled","conceptCode":"C18138","definition":"Any compound that has been joined with a radioactive substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DBEFD1A-1424-6963-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8F11F11-6780-8372-E040-BB89AD43620E","beginDate":"2013-10-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-17","modifiedBy":"ONEDATA","dateModified":"2013-10-17","deletedIndicator":"No"},{"value":"Alemtuzumab (Campath)","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F86AA949-1805-1CEA-E040-BB89AD434C7C","beginDate":"2013-10-17","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-05-02","modifiedBy":"ONEDATA","dateModified":"2014-05-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2741174","version":"1","preferredName":"Monoclonal Antibody Type","preferredDefinition":"An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:Type; a subdivision of a particular kind of thing.","longName":"C20401:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FE73-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"ONEDATA","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"554A7B34-10B3-5F55-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"NYCHM","dateModified":"2014-05-02","changeDescription":"08-25-08: Added permissible values.  Changed the max length from 32 to 40 - RA Added PV for 2400. AK 10/17/13. 5/2/14mn-updated pv name from Alemtuzumab to Alemtuzumab (Campath) for F2000 & F2400.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set â€“ Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedSubstanceAdministration:negationIndicator","type":"HCT_BRIDG_5","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the type of monoclonal antibody administered?","type":"Alternate Question Text","description":"What was the type of monoclonal antibody administered?","url":null,"context":"NHLBI"},{"name":"What was the monoclonal antib","type":"Preferred Question Text","description":"What was the monoclonal antibody that was administered?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EF4E1CD-3F78-5268-E053-F662850ABA98","latestVersionIndicator":"Yes","beginDate":"2017-05-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-07","modifiedBy":"ALEYR","dateModified":"2019-04-13","changeDescription":"System generated def displayed as alt def. released 8/28/17; Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}